Tuesday, November 13, 2018
Print Current Session:
|
|
Tuesday
SESSION 8:
CONTROVERSIES AND NEW DEVELOPMENTS IN THE MANAGEMENT OF UNCOMPLICATED TBADs
|
|
SESSION 8 SCHEDULE | |
4:48 PM - 4:53 PM | New Developments In The Endovascular Treatment Of Uncomplicated TBAD Patients: The FLIRT Concept: What Has Changed: TEVAR Is Indicated In Most At 2-8 Weeks After Onset: Who Are They And What Else Is Needed |
Presenter(s):Christoph A. Nienaber, MD, PhD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
4:54 PM - 4:59 PM | Trends In US National Treatment For Asymptomatic Uncomplicated TBADs: From The National Inpatient Sample Through 2015 |
Presenter(s):Raghuveer Vallabhaneni, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:00 PM - 5:05 PM | When Should Acute Uncomplicated TBADs Be Treated By TEVAR: How Can Imaging Help |
Presenter(s):Rachel E. Clough, MD, PhD, FRCS Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:06 PM - 5:11 PM | Outcomes Of Endovascular Repair Of Multi-Channeled Aortic Dissection With And Without Full True Lumen Collapse |
Presenter(s):Weiguo Fu, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:12 PM - 5:17 PM | DEBATE: The Case For Treating All Uncomplicated Acute TBAD Patients With TEVAR |
Presenter(s):Ross Milner, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:18 PM - 5:23 PM | DEBATE: The Case Against TEVAR For All Uncomplicated Acute TBAD Patients And For Good Medical Treatment Alone For Most: What Constitutes Good Medical Treatment |
Presenter(s):Ali Azizzadeh, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:24 PM - 5:29 PM | Patient Compliance With Good Medical Therapy For TBADs Is Poor: How Can This Be Improved And What Is Its Impact On The Debate Over Optimal Treatment For These Patients |
Presenter(s):Colin D. Bicknell, MD FRCS Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:30 PM - 5:35 PM | Another Controversial Opinion: Why TEVAR Should Be Performed On All Acute TBAD Patients |
Presenter(s):Mark Conrad, MD, MMSc Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:36 PM - 5:41 PM | A Different Controversial Opinion: Not So: Why TEVAR Should Only Be Performed Selectively On Patients With Uncomplicated Acute TBADs |
Presenter(s):Michel Makaroun, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:42 PM - 5:47 PM | DEBATE: Why A Randomized Controlled Trial (RCT) Of TEVAR And Medical Treatment vs. Medical Treatment Alone Is Needed For Acute Uncomplicated TBADs: Such A Trial (INTACT-AD) Has Been Designed With The Following Features . . . |
Presenter(s):Firas F. Mussa, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:48 PM - 5:53 PM | DEBATE: We Don’t Need Such A RCT: Data From The SVS Registry And Other Sources Will Suffice |
Presenter(s):Richard P. Cambria, MD Location: Grand Ballroom West, 3rd Floor |
|
View Slides in PDF | |
5:54 PM - 6:02 PM | Panel Discussion End of Program A |
END OF SESSION 8 | |
previous | next |